20-F: Evogene Shifts Focus to AI-Driven Small Molecules Amid Losses

Evogene Ltd. reported a strategic shift to focus on its ChemPass AI platform for small molecule discovery in pharma and agriculture, alongside significant operating losses and a going concern warning for 2025.

Summary

• Evogene is undergoing a strategic shift to focus solely on its ChemPass AI computational generative AI engine for small-molecule discovery in the pharmaceutical and agricultural industries, discontinuing investment in MicroBoost AI and GeneRator AI.
• The company reported an operating loss from continuing operations of $14.034 million for the year ended December 31, 2025, an improvement from $18.804 million in 2024 and $22.231 million in 2023.
• Total revenues decreased by 30.4% to $3.853 million in 2025 from $5.577 million in 2024, primarily due to lower revenue from AgPlenus and the completion of a collaboration agreement with Corteva.
• Cost of revenues increased by 70.8% to $4.094 million in 2025, largely due to a $2.180 million inventory impairment recorded by Casterra related to ceasing operations in Kenya.
• Net cash used in operating activities was $13.502 million in 2025, compared to $19.700 million in 2024.
• Management identified conditions raising substantial doubt about the company's ability to continue as a going concern, including a history of operating losses and negative cash flows, and an accumulated deficit of $282.556 million as of December 31, 2025.
• Lavie Bio's majority activity and the MicroBoost AI for AG platform were sold to ICL in July 2025 for $18.714 million, resulting in a gain on sale of approximately $6.4 million included in discontinued operations.
• Biomica licensed its BMC128 therapeutic candidate to Shanghai Lishan Biopharmaceuticals Co., Ltd. (Lishan Biotech) in February 2026, granting exclusive worldwide rights for development, manufacturing, and commercialization.
• Casterra Ag Ltd. streamlined its operations, focusing on the Brazilian market after a reduction in activity from its principal customer in Africa, and recorded a significant inventory impairment.
• Evogene completed a first-in-class foundation model for generative molecule design in collaboration with Google Cloud in June 2025 and initiated a second collaboration in February 2026 to integrate advanced AI agents into ChemPass AI.
• The company completed an At-The-Market (ATM) offering in September 2025, issuing 1,913,650 ordinary shares for gross proceeds of approximately $4.415 million in 2025.
• A warrant inducement transaction in February 2026 generated gross proceeds of approximately $3.385 million from the exercise of existing warrants.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for Evogene, marked by continued significant losses, a going concern warning, and Nasdaq delisting risk. While strategic shifts and new collaborations offer long-term potential, the immediate financial health and market position are concerning.

Positives

• Operating loss from continuing operations decreased to $14.034 million in 2025 from $18.804 million in 2024, indicating improved cost control.
• The sale of Lavie Bio's majority activity and the MicroBoost AI for AG platform to ICL generated $18.714 million in cash proceeds and a gain on sale of approximately $6.4 million.
• Biomica secured an exclusive worldwide licensing agreement for its BMC128 therapeutic candidate with Lishan Biotech, which includes potential development milestones and royalties on future sales.
• Evogene completed a first-in-class foundation model for generative molecule design in collaboration with Google Cloud, demonstrating technological advancement.
• A second collaboration with Google Cloud was initiated in February 2026 to integrate advanced AI agents into ChemPass AI, aiming to enhance discovery capabilities and scalability.
• AgPlenus discovered a new mode of action for fungicides against wheat disease, indicating progress in its R&D pipeline.
• Casterra's commercial castor seed varieties (701, 712, 716) demonstrated high commercial potential and attractive economic viability in Brazilian field trials during 2025.
• Evogene received an EU Horizon grant for the Crop4Clima project, which successfully completed its proof of concept and overall project by December 31, 2025, for developing oil-seed crops with enhanced CO2 assimilation and drought tolerance.
• An IIA approval was obtained in 2026 for a grant of NIS 1.5 million (approximately $485 thousand) for a program related to precision therapeutics for rare diseases.

Negatives

• The company has a history of operating losses and negative cash flow, with an accumulated deficit of $282.556 million as of December 31, 2025.
• Management identified conditions that raise substantial doubt about the company's ability to continue as a going concern.
• Total revenues decreased by 30.4% in 2025 compared to 2024, primarily due to lower AgPlenus revenue and the completion of a Corteva collaboration.
• Cost of revenues increased significantly in 2025 due to a $2.180 million inventory impairment by Casterra, mainly from ceasing operations in Kenya.
• The company's ordinary shares were trading below $1.00 per share as of March 12, 2026, raising concerns about Nasdaq listing compliance and potential delisting, especially given a previous reverse stock split in July 2024.
• Biomica significantly reduced its internal R&D activity and headcount in June 2025, and its activity is expected to cease by the end of Q2 2026 after completing its clinical trial.
• Casterra's activity has been streamlined due to a reduction in demand from its principal customer in Africa, leading to a focus shift to the Brazilian market and plans to sell African seed inventory as grains.
• Lavie Bio terminated its licensing agreement with Corteva in November 2024, regaining rights but losing potential milestone payments and royalties from that partnership.
• Casterra initiated legal proceedings against Titan Castor Farms Limited for a $1 million prepayment, and Titan is currently in breach of a consent judgment for repayment.

Risks

• History of operating losses and negative cash flow, with no assurance of achieving or maintaining profitability.
• Need for substantial additional capital in the future, which may dilute existing shareholders or require relinquishing rights to product candidates or intellectual property.
• Increased operational concentration risk and reduced diversification due to strategic streamlining and reduction of active subsidiaries, amplifying the impact of setbacks in remaining core activities.
• Discoveries and product candidates may not result in commercially viable products, and the product development cycle is lengthy and uncertain.
• Inability to maintain the ChemPass AI technological engine could substantially reduce research and development activities.
• Failure to efficiently produce and scale products, whether in-house or through third-party contractors, could hinder commercialization goals.
• Dependence on a few collaborators to develop and commercialize product candidates, with a reduced number of major companies in the agriculture industry for new partnerships.
• Decrease in research expenditures by major companies in target markets may jeopardize existing collaborations or ability to enter new ones.
• Operating in multiple industries with competitors having much greater resources, potentially diluting financial resources and suffering financial results.
• Efforts to develop and commercialize novel small molecule-based therapeutics (ChemPass AI) may be unsuccessful due to limitations of predictive models, preclinical failure, intellectual property risks, competition, regulatory hurdles, funding constraints, and data quality issues.
• Efforts to develop and commercialize novel ag-chemical products (AgPlenus) may be unsuccessful due to failure of target-based approach, cost-effective production, IP protection, funding, regulatory requirements, and supply chain disruptions (e.g., Ukraine supplier).
• Efforts to develop and commercialize seed-trait products (Ag-Seeds division) may be unsuccessful due to failure to identify genomic elements, IP protection, funding, development completion, and regulatory requirements.
• Biomica's future prospects are substantially dependent on a third-party licensee (Lishan Biotech) for the successful development and commercialization of BMC 128, with no assurance of meaningful value realization.
• Efforts to develop and commercialize castor seeds for industrial applications (Casterra) may be unsuccessful in achieving commercial presence due to failure to reach desired yields, establish efficient harvest/processing, large-scale grower adoption, address health/environmental risks (ricin), comply with regulations, or engage new buyers.
• Even if entitled to royalties from collaborators, actual receipt may be difficult, potentially resulting in costly litigation and loss of reputation.
• Intense competition for highly skilled scientific, technical, and other personnel, potentially leading to failure to attract, recruit, retain, and develop qualified employees.
• Need to finance the cost of developing certain product candidates independently, involving higher risks and potential dilution from traditional financing sources.
• Business and collaborators are subject to various government regulations; failure to comply or obtain necessary approvals could halt operations or increase costs.
• Disruption to information technology and systems, including cybersecurity threats and reliance on cloud computing services, could adversely affect reputation and demand.
• Need to obtain licenses for third-party technology that may not be available or only on commercially unreasonable terms.
• Exclusive licenses granted to collaborators may limit opportunities for additional licensing arrangements.
• Significant liabilities from product liability, warranty liability, or personal injury claims and litigation, especially given the handling of potentially toxic materials (e.g., ricin in castor seeds).
• Termination of leases, altering terms, or being locked into long-term leases may threaten operations and significantly impact financial status.
• Operations in South America and contracts with foreign businesses expose the company to additional market and operational risks.
• Growing cycles and adverse weather conditions may decrease results from operations.
• Dependence on ability to protect intellectual property and proprietary technologies; changes to patent laws may impair protection.
• Risk of being sued for infringing third-party intellectual property rights, leading to costly and time-consuming litigation.
• May be required to pay royalties to employees for service inventions, despite waivers.
• Changes in U.S. patent law could diminish the value of patents.
• Employment agreements may not adequately prevent disclosure of trade secrets, and non-compete covenants may not be fully enforceable.
• Conditions in Israel, including armed conflicts and regional instability, could adversely impact business and operations.
• U.S. shareholders owning at least 10% of ordinary shares may face adverse U.S. federal income tax consequences.
• Classification as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes in 2025, with a risk of being classified as such in 2026, potentially leading to adverse tax consequences for U.S. shareholders.
• Exchange rate fluctuations between the U.S. dollar and the NIS may negatively affect financial results.
• Terms of Israeli government grants may require satisfying specified conditions to manufacture products or transfer technologies outside of Israel, potentially incurring penalties.
• Shareholder rights and responsibilities governed by Israeli law, which may differ from U.S. corporations.
• Provisions of Israeli law may delay, prevent, or make undesirable an acquisition of all or a significant portion of shares or assets.
• Price of ordinary shares may fluctuate significantly, with no guarantee of a continuing public market.
• Inability to meet Nasdaq listing requirements (e.g., minimum bid price) may lead to delisting.
• Dual reporting obligations in Israel and the U.S. may increase compliance costs and distract management.
• Failure to maintain effective internal control over financial reporting could adversely affect share price.
• Evolving corporate governance and public disclosure regulations and expectations, including ESG matters, could expose the company to numerous risks and increased costs.

Future Outlook

Evogene expects to continue developing its product pipelines and initiate new collaborations in 2026, with an increased focus on strategic relationships for joint product development. The company also aims to evolve its organization and explore new areas where ChemPass AI can provide a competitive advantage and create value in a relatively short period. Sources of liquidity for 2026 are expected to include cash on hand, proceeds from collaboration and licensing agreements, grants, and other financing transactions, including by subsidiaries. The company may also pursue M&A transactions for inorganic growth.

Management Comments

• "This collaboration ensures that BMC128 continues to advance toward its next clinical milestones. We are impressed by the effects observed with BMC128 in lung and renal cancer patients who had experienced disease progression prior to treatment, and we look forward to advancing the program through further development and ultimately toward commercialization, for the benefit of cancer patients worldwide." Dr. Weijie Chen, Chairman of Lishan Biotech (regarding Biomica's BMC128 licensing agreement).
• "We are pleased to partner with Lishan Biotech as BMC128 enters its next phase of development. Lishan Biotech's strong development capabilities and commitment to innovative microbiome-based therapeutics position this program for meaningful value creation in difficult-to-treat cancers. As a major shareholder of Biomica, Evogene expects to benefit from BMC128's future success." Ofer Haviv, CEO of Evogene and Biomica (regarding Biomica's BMC128 licensing agreement).
• "We are very pleased to see the execution of this meaningful and impactful collaboration agreement. This partnership brings together China's clinical development capabilities with Israel's innovation in microbiome science. We believe the success of this project will benefit patients worldwide and contribute to important breakthroughs in microbiome-based therapeutics." Dr. Jing Bao, MD, Director (Board Member) of Biomica Ltd (regarding Biomica's BMC128 licensing agreement).

Industry Context

StockSavvy.ai notes that Evogene's strategic pivot towards AI-driven small molecule discovery in both pharmaceutical and agricultural sectors aligns with broader industry trends emphasizing computational approaches for accelerated R&D. The divestment of non-core assets and streamlining of subsidiaries, while reducing diversification, allows for a more focused allocation of resources to its core ChemPass AI platform. The collaborations with Google Cloud, Tel Aviv University, Unravel Biosciences, and Systasy Bioscience demonstrate a commitment to leveraging external expertise and funding, a common strategy for biotech firms with limited internal resources. However, the highly consolidated nature of the agriculture industry, as highlighted in the risks, presents challenges for new collaborations and growth opportunities. The company's move into AI-driven drug discovery places it in a competitive landscape with both established pharmaceutical giants and emerging AI-biotech startups, all vying for efficient molecule identification and optimization.

Comparison to Industry Standards

• Evogene's reported design precision levels of approximately 90% for its generative AI model, developed in collaboration with Google Cloud, are stated to exceed prevailing industry benchmarks at the time, suggesting a competitive edge in computational molecule design.
• The global crop protection chemicals market was estimated at approximately $91.4 billion in 2023 and is expected to grow to over $132 billion by 2032 (Global Market Insight), indicating a substantial market opportunity for AgPlenus's ag-chemical products, though competition is intense from major players like BASF, Bayer, Syngenta Group, FMC, and Corteva.
• The global castor oil market is projected to grow from an estimated value of $1.36 billion in 2025 to reach $1.83 billion by 2035 (CAGR of 3.2%), providing a growing, albeit specialized, market for Casterra's improved castor bean seeds. Casterra's competition includes companies like Kaiima Seeds and Terasol.
• The company's reliance on collaborations for later-stage development and commercialization is a common model for early-stage biotech companies, mitigating the high costs and risks associated with full-scale drug and agricultural product development internally.

Management Changes

Corporate Governance

Legal Proceedings

• Casterra has initiated legal proceedings in Zambia against Titan Castor Farms Limited for the recovery of approximately $1 million, paid as a pre-payment for castor seeds that were not provided. A consent judgment was entered on March 4, 2025, for Titan to repay the debt in installments, but Titan is currently in breach of this judgment.

Related Party Transactions

• Corteva (through its subsidiary Pioneer Hi-Bred International, Inc.) holds 26.57% of Lavie Bio Ltd.'s shares and was a major customer of Evogene, contributing $350,000 in revenues in 2025.
• Transactions with officers and certain shareholders are disclosed, including compensation and share-based compensation for directors and executive officers, and revenues from major customers who are also shareholders.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing capital raises and potential future equity offerings, as well as the risk of delisting from Nasdaq due to the share price falling below the minimum bid requirement.
• Employees have been significantly impacted by workforce reductions and streamlining of activities across subsidiaries, particularly in Biomica and Casterra, leading to a decrease in total employee count from 142 in 2023 to 52 in 2025.
• Customers and collaborators may experience changes in product development focus and service offerings due to the strategic shift and divestment of certain subsidiary activities, though new collaborations aim to maintain engagement.
• Creditors face risks associated with the company's history of operating losses and negative cash flow, as well as the going concern warning, although management has a plan to address liquidity needs.

Next Steps

• Biomica to complete the wrap-up of its Phase 1 clinical trial for BMC128 by June 2026.
• Lishan Biotech plans to advance BMC128 into a Phase 2 clinical study and pursue regulatory filings in China and the United States.
• Casterra to focus most of its efforts on the Brazilian market and sell its seed inventory in Africa as grains.
• Evogene expects to continue developing its product pipelines and initiate new collaborations with an increased focus on strategic relationships for joint product development in 2026.
• Evogene to continue to evolve its organization and examine new areas for ChemPass AI application.
• Evogene to finance operations through equity or debt financings if needed, and explore exit opportunities for certain subsidiaries.
• Ms. Polina Ravzin will assume the responsibilities of Chief Financial Officer as of April 1, 2026.
• Mr. Ofer Haviv will replace Mr. Yoash Zohar as Casterra's Chief Executive Officer, effective April 1, 2026.
• Evogene to integrate advanced AI agents into ChemPass AI using Vertex AI in collaboration with Google Cloud.
• Evogene to receive a grant of NIS 1.5 million (approximately $485 thousand) for a program related to precision therapeutics to rare disease in 2026.
• Biomica anticipates distributing the majority of its remaining cash to its shareholders, including Evogene, following court approval for a dividend of up to $2.7 million.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a history of significant operating losses, negative cash flow, and an accumulated deficit of over $282 million. Management's explicit disclosure of 'substantial doubt about our ability to continue as a going concern' is a critical red flag. Furthermore, the stock price has fallen below $1.00, triggering Nasdaq delisting concerns, which could severely impair liquidity and investor confidence. While strategic shifts and new collaborations offer long-term potential, the immediate financial outlook is highly precarious, and the risk of further capital raises at dilutive terms or even bankruptcy is substantial. A seasoned investor would prioritize capital preservation and exit this position.

Keywords

Evogene, ChemPass AI, Small Molecules, Pharmaceutical, Agriculture, Biotechnology, Genomic Elements, Crop Protection, Microbiome, Castor Seeds, SEC Filing, 20-F, Financial Results, Operating Loss, Going Concern, Nasdaq Delisting, Capital Raise, Strategic Shift, R&D, Intellectual Property, Israel Innovation Authority, Google Cloud, Lishan Biotech, ICL Group, Biomica, Casterra, AgPlenus, Finally Foods